Merck, known as MSD outside the United States and Canada, today announced it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025), taking place from October 15–18, 2025, in Paris, France.

At the conference, Merck will showcase results from several key clinical studies that reinforce its continued commitment to advancing innovative solutions in HIV treatment and prevention. The company will share new analyses from its Phase 3 program evaluating the investigational once-daily, two-drug regimen doravirine/islatravir (DOR/ISL, 100mg/0.25mg) compared with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF, 50mg/200mg/25mg) for adults with virologically suppressed HIV-1 infection on antiretroviral therapy.

In addition, Merck will present data on weight and body composition outcomes at Week 48 from the same Phase 3 study, along with findings on fasting lipids and insulin resistance from two companion Phase 3 trials comparing DOR/ISL to baseline antiretroviral therapy or BIC/FTC/TAF.

Further, the company will report 96-week safety and pharmacokinetics data from a Phase 2 trial of the investigational once-weekly oral combination of islatravir and lenacapavir (MK-8591D) in adults with virologically suppressed HIV-1 infection. Merck will also share Phase 1 data evaluating the safety and pharmacokinetics of MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP), in adults with moderate or severe renal impairment.

“We are pleased to share new data from across our HIV pipeline at EACS 2025, including additional analyses from the Phase 3 program of the investigational once-daily, two-drug treatment regimen DOR/ISL, which is currently under review by the U.S. Food and Drug Administration,” said Dr. Luisa Stamm, associate vice president and HIV section head at Merck Research Laboratories. “By advancing multiple investigational agents for daily and weekly treatment, as well as monthly oral prevention, we aim to offer individuals new and flexible options to treat and prevent HIV.”

Merck remains committed to driving innovation in HIV science and improving outcomes for people living with and at risk of HIV worldwide.